文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肝细胞 IKKβ/NF-κB 通过阻止氧化应激驱动的 STAT3 激活来抑制肿瘤促进和进展。

Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

机构信息

Laboratory of Gene Regulation and Signal Transduction, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

出版信息

Cancer Cell. 2010 Mar 16;17(3):286-97. doi: 10.1016/j.ccr.2009.12.048.


DOI:10.1016/j.ccr.2009.12.048
PMID:20227042
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2841312/
Abstract

The NF-kappaB activating kinase IKKbeta suppresses early chemically induced liver tumorigenesis by inhibiting hepatocyte death and compensatory proliferation. To study IKKbeta's role in late tumor promotion and progression, we developed a transplant system that allows initiated mouse hepatocytes to form hepatocellular carcinomas (HCC) in host liver after a long latency. Deletion of IKKbeta long after initiation accelerated HCC development and enhanced proliferation of tumor initiating cells. These effects of IKKbeta/NF-kappaB were cell autonomous and correlated with increased accumulation of reactive oxygen species that led to JNK and STAT3 activation. Hepatocyte-specific STAT3 ablation prevented HCC development. The negative crosstalk between NF-kappaB and STAT3, which is also evident in human HCC, is a critical regulator of liver cancer development and progression.

摘要

NF-κB 激活激酶 IKKβ通过抑制肝细胞死亡和代偿性增殖来抑制早期化学诱导的肝癌发生。为了研究 IKKβ在晚期肿瘤促进和进展中的作用,我们开发了一种移植系统,该系统允许起始的小鼠肝细胞在长时间潜伏期后在宿主肝脏中形成肝细胞癌(HCC)。起始后长时间缺失 IKKβ会加速 HCC 的发展并增强肿瘤起始细胞的增殖。IKKβ/NF-κB 的这些作用是细胞自主性的,并与导致 JNK 和 STAT3 激活的活性氧物质的积累增加相关。肝细胞特异性 STAT3 缺失可防止 HCC 的发生。NF-κB 和 STAT3 之间的负交叉对话在人 HCC 中也很明显,是肝癌发生和进展的关键调节因子。

相似文献

[1]
Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

Cancer Cell. 2010-3-16

[2]
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.

Proc Natl Acad Sci U S A. 2006-7-11

[3]
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.

Cell. 2005-7-1

[4]
NF-κB and STAT3 - key players in liver inflammation and cancer.

Cell Res. 2010-12-28

[5]
NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.

Cancer Cell. 2015-11-9

[6]
Targeted deletion of hepatocyte Ikkbeta confers growth advantages.

Biochem Biophys Res Commun. 2009-3-6

[7]
Canonical NF-κB signaling in hepatocytes acts as a tumor-suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response.

Hepatology. 2016-3-4

[8]
Ikappa B kinasebeta/nuclear factor-kappaB activation controls the development of liver metastasis by way of interleukin-6 expression.

Hepatology. 2009-12

[9]
Dual role for inositol-requiring enzyme 1α in promoting the development of hepatocellular carcinoma during diet-induced obesity in mice.

Hepatology. 2018-5-21

[10]
Conditional deletion of IkappaB-kinase-beta accelerates helicobacter-dependent gastric apoptosis, proliferation, and preneoplasia.

Gastroenterology. 2009-12-4

引用本文的文献

[1]
Decoding Hepatocellular Carcinoma Metastasis: Molecular Mechanisms, Targeted Therapies, and Potential Biomarkers.

Curr Issues Mol Biol. 2025-4-8

[2]
Therapeutic efficacy of canagliflozin against hepatocarcinogenesis induced by CDD/DEN/TAA in a rat model: regulation of AMPK/HIF-1α/YAP-1/TAZ signaling pathways.

Naunyn Schmiedebergs Arch Pharmacol. 2025-5-29

[3]
The Impact of Microwave Ablation on Recurrence and Metastasis of Hepatocellular Carcinoma: Insights From Animal Studies and Cytokine Profiling.

J Hepatocell Carcinoma. 2025-4-26

[4]
T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells.

Naunyn Schmiedebergs Arch Pharmacol. 2025-3-18

[5]
Novel insights into the impact of liver inflammatory responses on primary liver cancer development.

Liver Res. 2023-2-3

[6]
Napabucasin-loaded PLGA nanoparticles trigger anti-HCC immune responses by metabolic reprogramming of tumor-associated macrophages.

J Transl Med. 2024-12-20

[7]
Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance.

Cancers (Basel). 2024-11-25

[8]
Blocking interleukin-1 receptor type 1 (IL-1R1) signaling in hepatocytes slows down diethylnitrosamine-induced liver tumor growth in obese mice.

Hepatol Commun. 2024-11-29

[9]
NF-κB signaling pathway in tumor microenvironment.

Front Immunol. 2024

[10]
Dietary Rhythms and MASLD-Related Hepatocellular Carcinoma.

Cancers (Basel). 2024-10-14

本文引用的文献

[1]
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Cancer Cell. 2009-12-8

[2]
A lymphotoxin-driven pathway to hepatocellular carcinoma.

Cancer Cell. 2009-10-6

[3]
Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences.

Int J Cancer. 2009-11-15

[4]
High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B.

Int J Cancer. 2009-6-15

[5]
Inflammation and liver cancer: new molecular links .

Ann N Y Acad Sci. 2009-2

[6]
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Cancer Cell. 2009-2-3

[7]
gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.

Cancer Cell. 2009-2-3

[8]
Inflammation and cancer: IL-6 and STAT3 complete the link.

Cancer Cell. 2009-2-3

[9]
Targeted deletion of hepatocyte Ikkbeta confers growth advantages.

Biochem Biophys Res Commun. 2009-3-6

[10]
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.

Oncogene. 2009-2-19

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索